Immune response evolution in peanut epicutaneous immunotherapy for peanut-allergic children

Area of Science:

• Immunology
• Allergy Research
• Clinical Trials

Background:

• Epicutaneous immunotherapy (EPIT) using Viaskin™ Peanut (DBV712) has shown efficacy in desensitizing peanut-allergic children.
• Predictive serologic biomarkers for treatment response remain unclear.

Purpose of the Study:

• To investigate serum-specific IgG4 and IgE trajectories.
• To identify predictors of treatment response to Viaskin Peanut.

Main Methods:

• Analysis of serum samples from a phase 3 clinical trial (NCT02577772).
• Exploratory univariate and multivariate analyses of peanut-specific IgG4 and IgE (whole peanut and components).
• Correlation with peanut protein eliciting dose (ED) from Month 12 food challenge.

Main Results:

• Viaskin Peanut treatment led to significant increases in peanut sIgG4 and a transient rise then fall in peanut sIgE.
• Higher Month 12 peanut sIgG4/sIgE ratios were associated with treatment response (p < 0.001).
• Peanut sIgG4/sIgE ratio >20.1 predicted higher ED (≥300 mg) with 80% PPV; Ara h 1 sIgE also showed predictive value.

Conclusions:

• Rising peanut sIgG4 levels effectively differentiate Viaskin Peanut treatment from placebo.
• Specific IgG4/IgE ratios and combined biomarkers show moderate predictive ability for treatment response.
• Further data are needed to confirm the clinical utility of these biomarkers for monitoring.